[1]. Lombardi P, Filetti M, Falcone R, et al. Overview of Trop-2 in Cancer: From PreClinical Studies to Future Directions in Clinical Settings. Cancers.2023;15(6):1744.
[2]. Shvartsur, A.; Bonavida, B. Trop2 and its overexpression in cancers: Regulationand clinical/therapeutic implications. Genes Cancer 2015, 6, 84–105.
[3]. Lipinski, M.; Parks, D.R.; Rouse, R.V.; Herzenberg, L.A. Human trophoblast cellsurface antigens defined by monoclonal antibodies. Proc. Natl. Acad. Sci. USA1981, 78, 5147–5150.
[4]. Trerotola, M.; Jernigan, D.L.; Liu, Q.; Siddiqui, J.; Fatatis, A.; Languino, L.R. Trop-2promotes prostate cancer metastasis by modulating β integrin functions.Cancer Res. 2013, 73, 3155–3167.
[5]. Bignotti, E.; Zanotti, L.; Calza, S.; Falchetti, M.; Lonardi, S.; Ravaggi, A.; Romani,C.; Todeschini, P.; Bandiera, E.; Tassi, R.A.; et al. Trop-2 protein overexpression isCN-136072 Expiration Date: 2025-6-21an independent marker for predicting disease recurrence in endometrioidendometrial carcinoma. BMC Clin. Pathol. 2012, 12, 22.
[6]. Cubas, R.; Zhang, S.; Li, M.; Chen, C.; Yao, Q. Trop2 expression contributes totumor pathogenesis by activating the ERK MAPK pathway. Mol. Cancer 2010, 9,253.
[7]. Guan, H.; Guo, Z.; Liang, W.; Li, H.; Wei, G.; Xu, L.; Xiao, H.; Li, Y. Trop2 enhancesinvasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways.BMC Cancer 2017, 17, 486.
[8]. Guerra, E.; Trerotola, M.; Tripaldi, R.; Aloisi, A.L.; Simeone, P.; Sacchetti, A.; Relli,V.; D’Amore, A.; La Sorda, R.; Lattanzio, R.; et al. Trop-2 Induces Tumor GrowthThrough AKT and Determines Sensitivity to AKT Inhibitors. Clin. Cancer Res.2016, 22, 4197–4205.
[9]. El Sewedy, T.; Fornaro, M.; Alberti, S. Cloning of the murine TROP2 gene:Conservation of a PIP2-binding sequence in the cytoplasmic domain of TROP-2. Int. J. Cancer 1998, 75, 324–330.